Full text
=========

Purpose
-------

To determine the optimal time within the APRV phase cycle to accurately measure PaOP.

Methods
-------

Ten consecutive patients with acute lung injury (ALI) managed with PCV and a pulmonary artery catheter (PAC) were studied. Demographic data was recorded. Patients served as their own controls and were ventilated by a Drager Evita 4 Pulmonary Workstation. No patients received paralytics. PCV settings (AC mode) achieved a pCO~2~ of 35--45 (torr) and a pO~2~ \> 60 (torr) on 60% O~2~; PEEP was not controlled. Hemodynamic profiles were recorded 30 min after achieving the above pCO~2~ and pO~2~values. Patients were then changed to APRV to achieve the same pCO~2~ and pO~2~ values and hemodynamic measurements were repeated at 30 min. All medications were held constant. PaOP tracings (mmHg) were recorded and compared to the downloaded flow-time trace from the ventilator (Evitaview software). The PCV PaOP was recorded at the end of exhalation and served as the standard for comparisons. PaOP was recorded during the APRV phase cycle (positive pressure and release) and compared to the PCV value. Data are shown as means ± standard deviation and were compared using a two-tailed paired t-test; significance assumed for *P* \< 0.05.

Results
-------

Principal diagnoses were trauma (66%), abdominal sepsis (32%), and other (2%). Mean age was 54 ± 6.2years. PCV blood gas values were pH 7.34 ± 0.04, pCO~2~39.3 ± 3.8, pO~2~ 77.4 ± 9.5. APRV blood gas values were pH 7.37 ± 0.03, pCO~2~ 35.5 ± 2.8, pO~2~ 98 ± 11, (*P*\< 0.05 vs PCV). The PCV PaOP was 16.3 ± 3 on a PEEP of 13.6 ± 2.2 cmH~2~O with a CI of 3.2 ± 0.5 L/min/m^2^ and an SvO~2~ of 76.8 ± 4.5% at a hemoglobin of 9.6 ± 1.04 gm%.The APRV PaOP during the positive pressure phase was 21.2 ± 3.3 (initial), 19 ± 2.5 (mid), and 20.5 ± 2.8 (end); *P*\<0.01 for all versus PCV. The APRV PaOP during the release phase was 19 ± 2.7 (initial, *P* \< 0.05), 17.7 ± 2.3 (mid, *P* = 0.09), and 16.4 ± 2.6 (end, *P* = 0.9). CI was significantly increased at 3.6 ± 0.4 (*P*\<0.01 vs PCV) while SvO~2~ was unchanged at 79.1 ± 4.1 (*P*\> 0.05 vs PCV).

Conclusions
-----------

APRV increases the measured PaOP during the positive pressure phase. PaOP may be reliably measured at the midpoint or end of the release phase of APRV. APRV increases oxygenation and cardiac index compared to PCV in patients with acute lung injury.
